O’Brien will oversee the development of U.S. market access strategy and implementation, as well as payer contracting and reimbursement initiatives, to enable patient access to RADICAVA and future pipeline products.
| |
| [21-November-2017] |
| JERSEY CITY, N.J., Nov. 21, 2017 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the appointment of Kevin O’Brien as Vice President of Market Access and a member of the organization’s executive leadership team. In this role, O’Brien will oversee the development of U.S. market access strategy and implementation, as well as payer contracting and reimbursement initiatives, to enable patient access to RADICAVA® (edaravone) and future pipeline products. “Kevin O’Brien has a breadth of experience leading field reimbursement teams, developing meaningful patient support programs and directing national payer teams across many therapeutic areas,” said Atsushi Fujimoto, President, Mitsubishi Tanabe Pharma America. “With his extensive expertise in access, reimbursement and distribution, Kevin will be a key leader in our organization as we build upon the company’s solid foundation to drive continued growth in the U.S.” O’Brien brings MTPA more than 30 years of commercial experience in the pharmaceutical and medical device industry, having served in a wide range of roles ranging from field sales to executive leadership. Prior to MTPA, O’Brien served as Vice President of Market Access at Bioventus, where he was responsible for leading payer, trade, marketing, contracting, and government teams. Previously, O’Brien spent six years at Endo Pharmaceuticals, as Senior Director of Managed Markets. About Mitsubishi Tanabe Pharma America, Inc. Media inquiries:
View original content with multimedia:http://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-expands-executive-leadership-team-names-kevin-obrien-as-vice-president-of-market-access-300560234.html SOURCE Mitsubishi Tanabe Pharma America, Inc. |
